Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Triple-negative breast cancer: new perspectives for targeted therapies
Current taxane formulations and emerging cabazitaxel delivery systems